• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

作者信息

Lamarque Mathilde, Raynaud Sophie, Itzykson Raphael, Thepot Sylvain, Quesnel Bruno, Dreyfus Francois, Rauzy Odile Beyne, Turlure Pascal, Vey Norbert, Recher Christian, Dartigeas Caroline, Legros Laurence, Delaunay Jacques, Visanica Sorin, Stamatoullas Aspasia, Fenaux Pierre, Adès Lionel

出版信息

Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555.

DOI:10.1182/blood-2012-09-453555
PMID:23243156
Abstract
摘要

相似文献

1
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.修订后的国际预后评分系统（IPSS）是评估接受阿扎胞苷治疗的骨髓增生异常综合征（MDS）患者预后的有力工具：法国骨髓增生异常综合征研究组（GFM）的经验。
Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555.
2
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.接受阿扎胞苷治疗的高危骨髓增生异常综合征患者的长期结局：GFM 同情用药项目队列的更新
Blood. 2012 Jun 21;119(25):6172-3. doi: 10.1182/blood-2012-04-422204.
3
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.比较阿扎胞苷治疗骨髓增生异常综合征患者中修订后的国际预后评分系统和法国预后评分系统的预后预测价值。
Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.
4
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.基线细胞遗传学结果和细胞遗传学反应对接受阿扎胞苷治疗的高危骨髓增生异常综合征和低原始细胞计数急性髓系白血病结局的影响。
Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.
5
Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.根据国际预后评分系统（IPSS）细胞遗传学特征，阿扎胞苷治疗骨髓增生异常综合征的真实生活经验。
Am J Hematol. 2014 May;89(5):565. doi: 10.1002/ajh.23677. Epub 2014 Feb 28.
6
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.低剂量地西他滨治疗骨髓增生异常综合征患者的核型反应基于修订的 IPSS 核型风险分层和 FISH 微小残留病监测。
Leuk Res. 2013 Nov;37(11):1516-21. doi: 10.1016/j.leukres.2013.09.006. Epub 2013 Sep 18.
7
Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.阿扎胞苷治疗失败后骨髓增生异常综合征患者的预后预测：北美骨髓增生异常综合征联盟评分系统的验证
Haematologica. 2016 Oct;101(10):e427-e428. doi: 10.3324/haematol.2016.150714.
8
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes.中危骨髓增生异常综合征预后的优化及阿扎胞苷的疗效
Blood Cancer J. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4.
9
Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.对于接受阿扎胞苷治疗的骨髓增生异常综合征患者，细胞遗传学反应并非临床反应的先决条件。
Eur J Haematol. 2011 Aug;87(2):186-8. doi: 10.1111/j.1600-0609.2011.01653.x.
10
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.比较各种标准在预测接受阿扎胞苷治疗的骨髓增生异常综合征患者的治疗反应和预后中的作用。
Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19.

引用本文的文献

1
Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.接受阿扎胞苷治疗的骨髓增生异常综合征患者的真实世界结局及预后因素——一项回顾性分析
Cancers (Basel). 2024 Mar 29;16(7):1333. doi: 10.3390/cancers16071333.
2
[The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].[国际预后评分系统修订版（IPSS-R）和世界卫生组织预后评分系统（WPSS）在接受异基因造血干细胞移植的骨髓增生异常综合征患者中的移植前评估的预后意义]
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):247-254. doi: 10.3760/cma.j.issn.0253-2727.2022.03.011.
3
Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes.
个性化风险方案和机器学习赋能骨髓增生异常综合征的基因组预后模型。
Int J Mol Sci. 2022 Mar 3;23(5):2802. doi: 10.3390/ijms23052802.
4
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.血清铁蛋白和东部肿瘤协作组（ECOG）体能状态可预测接受5-氮杂胞苷治疗的高危骨髓增生异常综合征和少原始细胞急性髓系白血病患者的反应，并提高国际预后积分系统（IPSS）或国际预后积分系统修订版（IPSS-R）的预后价值：希腊骨髓增生异常和发育不全综合征国家登记处的回顾性分析
Ther Adv Hematol. 2020 Dec 8;11:2040620720966121. doi: 10.1177/2040620720966121. eCollection 2020.
5
Myelodysplastic syndromes: moving towards personalized management.骨髓增生异常综合征：走向个体化治疗。
Haematologica. 2020 Jul;105(7):1765-1779. doi: 10.3324/haematol.2020.248955. Epub 2020 May 21.
6
Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population.评估不同评分系统和基因突变对中国人群骨髓增生异常综合征（MDS）预后的影响。
J Cancer. 2020 Jan 1;11(2):508-519. doi: 10.7150/jca.30363. eCollection 2020.
7
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.骨髓中BCL2L10阳性细胞是骨髓增生异常综合征和急性髓系白血病中阿扎胞苷治疗结局的独立预后因素。
Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.
8
Monosomal karyotype in myeloid neoplasias: a literature review.髓系肿瘤中的单倍体核型：文献综述
Onco Targets Ther. 2017 Apr 20;10:2163-2171. doi: 10.2147/OTT.S133937. eCollection 2017.
9
Improving Prognostic Modeling in Myelodysplastic Syndromes.改善骨髓增生异常综合征的预后模型
Curr Hematol Malig Rep. 2016 Dec;11(6):395-401. doi: 10.1007/s11899-016-0342-1.
10
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.体细胞突变可预测骨髓增生异常综合征患者低甲基化治疗的疗效。
Oncotarget. 2016 Aug 23;7(34):55264-55275. doi: 10.18632/oncotarget.10526.